Epigenetic Approaches in Cancer Epidemiology (R21)

The summary for the Epigenetic Approaches in Cancer Epidemiology (R21) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Epigenetic Approaches in Cancer Epidemiology (R21)
	CFDA Number:	93.393
	CFDA Description:	Cancer Cause and Prevention Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Health Education
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	PA-07-299
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Jan 16, 2007
	Creation Date:	Jan 16, 2007
	Original Closing Date for Applications:	Multiple Receipt Dates - See Link to Full Announcement for details.
	Current Closing Date for Applications:	Information not provided
	Archive Date:	Dec 05, 2008
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	$200,000
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) Small businesses Public and State controlled institutions of higher education Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility: Foreign institutions are eligible to apply.
Grant Description: -Purpose. The purpose of this concept is to stimulate population-based epidemiology research on the roles of DNA methylation markers in cancer. -Mechanism of Support. This Funding Opportunity Announcement (FOA) will utilize the NIH developmental/exploratory (R21) grant mechanism and it runs in parallel with an FOA of identical scientific scope, PA-07-298, which solicits applications under the NIH research project (R01) grant mechanism. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PA-07-299.html http://grants.nih.gov/grants/guide/pa-files/PA-07-299.html
Grant Announcement Contact: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Alliance of Glycobiologists for Detection of Cancer (U01); • Cancer Target Discovery and Development (CTDD) Network (U01); • Community Clinical Oncology Program Research Bases (U10); • Minority-Based Community Clinical Oncology Program Groups (U10); • Community Clinical Oncology Program Groups (U10); • Pilot Studies in Pancreatic Cancer; • CANCER PREVENTION RESEARCH SMALL GRANT PROGRAM; • MOLECULAR TARGETS FOR NUTRIENTS IN PROSTATE CANCER PREVENTION; • Cancer Prevention Research Small Grant Program (R03); • Pilot Studies in Pancreatic Cancer (R03)